News | June 08, 2024
Lupin completes acquisition of two brands from Sanofi in Europe and Canada
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Further strengthens BaseLaunch's global pharma industry partnerships
Establishing Asymchem’s first manufacturing footprint in Europe
Subscribe To Our Newsletter & Stay Updated
